89ZR-CX-072-PET scan studie
5 mei 2021
Archief
ACT
12 april 2021
Optimal Timing of a tailored Physical Activity program during chemotherapeutic Cancer Treatment to reduce Long-term Cardiovascular Morbidity METc nr: 2012/260 Onderzoekscode: ON76 ClinicalTrials.gov registratie: NCT01642680 Samenvatting Het aantal…
ACT
ACT
ACT
ACT
ACT
ACT
6 mei 2021
Optimal Timing of a tailored Physical Activity program during chemotherapeutic Cancer Treatment to reduce Long-term Cardiovascular Morbidity METc nr: 2012/260 Onderzoekscode: ON76 ClinicalTrials.gov registratie: NCT01642680 Samenvatting Het aantal…
AIPAC
12 april 2021
Active Immunotherapy PAClitaxel: A multicentre, Phase IIb, randomized, double blind, placebo-controlled study in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-31g fusion protein) or placebo as adjunctive…
ALT-GIST EORTC 1321
ALT-GIST: A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST). EORTC study…
AMG 479
A phase 3, multicenter, randomized, double-blind, placebo controlled, trial of AMG 479 or placebo in combination with Gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas.
BLU-667
A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors. Protocolnummer: BLU-667-1101 Eudract…
BLU-667 studie (named-patient programma)
Zie BEACON: NET – medullair schildkliercarcinoom – palliatief – BLU-667 studie (named-patient programma)
Breast Optical Imaging
Validation of Uptake of a VEGF-targeted Optical Fluorescent Imaging Tracer in Surgical Specimens of Breast Cancer and Application of Pre- and Intra-operative Human Molecular Fluorescence Imaging Techniques. A…
CA209-143
Phase IIb Study of Nivolumab in comb. with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM) Protocolnummer: CA209143 Eudractnummer: 2013-003738-34 METc nummer: 2014525 Onderzoekscode: O118 ECG…
CA209-238
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at…
CA209-577
A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer. (CheckMate 577: CHECKpoint pathway and nivoluMab…
CA209-714
CA209-714: A double-blind, randomized, two arm phase 2 study of nivolumab in combination with ipilimumab versus nivolumab in combination with ipilimumab placebo squamous cell carcinoma of the head…
CA209-714
CA209-76K
A phase 3, randomized, double-blind study of adjuvant immunotherapy with Nivolumab versus placebo after complete resection of stage IIB/C melanoma (CA209-76K) Protocolnummer: CA20976K EudraCT nummer: 2019-001230-34 METc nummer:…